Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cue Biopharma (CUE) EBITDA (2018 - 2025)

Historic EBITDA for Cue Biopharma (CUE) over the last 8 years, with Q3 2025 value amounting to -$7.4 million.

  • Cue Biopharma's EBITDA rose 1400.69% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$37.7 million, marking a year-over-year increase of 1553.39%. This contributed to the annual value of -$40.7 million for FY2024, which is 1967.53% up from last year.
  • Cue Biopharma's EBITDA amounted to -$7.4 million in Q3 2025, which was up 1400.69% from -$8.5 million recorded in Q2 2025.
  • In the past 5 years, Cue Biopharma's EBITDA registered a high of -$7.4 million during Q3 2025, and its lowest value of -$14.6 million during Q4 2022.
  • Moreover, its 5-year median value for EBITDA was -$12.3 million (2025), whereas its average is -$11.4 million.
  • Per our database at Business Quant, Cue Biopharma's EBITDA crashed by 7408.72% in 2022 and then skyrocketed by 2931.37% in 2024.
  • Over the past 5 years, Cue Biopharma's EBITDA (Quarter) stood at -$8.4 million in 2021, then tumbled by 74.09% to -$14.6 million in 2022, then grew by 7.96% to -$13.4 million in 2023, then grew by 29.31% to -$9.5 million in 2024, then rose by 21.58% to -$7.4 million in 2025.
  • Its EBITDA was -$7.4 million in Q3 2025, compared to -$8.5 million in Q2 2025 and -$12.3 million in Q1 2025.